BiomX expects top-line results for BX 201 trial in Q1 2025 and BX 004 in H1 2026. The company has $24.7M in funds, expected to last until Q4 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
BiomX expects top-line results for BX 201 trial in Q1 2025 and BX 004 in H1 2026. The company has $24.7M in funds, expected to last until Q4 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.